TD Asset Management’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.6M | Buy |
127,878
+49,000
| +62% | +$997K | ﹤0.01% | 879 |
|
|
2025
Q1 | $1.43M | Sell |
78,878
-65,000
| -45% | -$1.18M | ﹤0.01% | 1028 |
|
|
2024
Q4 | $3.64M | Sell |
143,878
-20,200
| -12% | -$510K | ﹤0.01% | 851 |
|
|
2024
Q3 | $5.45M | Sell |
164,078
-25,600
| -13% | -$850K | ﹤0.01% | 777 |
|
|
2024
Q2 | $7.02M | Sell |
189,678
-35,800
| -16% | -$1.32M | 0.01% | 683 |
|
|
2024
Q1 | $9.46M | Buy |
225,478
+173,156
| +331% | +$7.27M | 0.01% | 636 |
|
|
2023
Q4 | $2.08M | Sell |
52,322
-12,600
| -19% | -$500K | ﹤0.01% | 995 |
|
|
2023
Q3 | $1.79M | Buy |
64,922
+32,461
| +100% | +$893K | ﹤0.01% | 989 |
|
|
2023
Q2 | $1.1M | Sell |
32,461
-13,300
| -29% | -$451K | ﹤0.01% | 1107 |
|
|
2023
Q1 | $1.65M | Sell |
45,761
-9,500
| -17% | -$342K | ﹤0.01% | 1029 |
|
|
2022
Q4 | $2.46M | Buy |
55,261
+7,600
| +16% | +$339K | ﹤0.01% | 926 |
|
|
2022
Q3 | $1.35M | Buy |
47,661
+11,000
| +30% | +$312K | ﹤0.01% | 1108 |
|
|
2022
Q2 | $988K | Sell |
36,661
-37,168
| -50% | -$1M | ﹤0.01% | 1182 |
|
|
2022
Q1 | $2.52M | Buy |
73,829
+11,500
| +18% | +$392K | ﹤0.01% | 1015 |
|
|
2021
Q4 | $2.41M | Hold |
62,329
| – | – | ﹤0.01% | 1092 |
|
|
2021
Q3 | $3.37M | Buy |
62,329
+17,400
| +39% | +$939K | ﹤0.01% | 934 |
|
|
2021
Q2 | $1.97M | Buy |
44,929
+22,079
| +97% | +$966K | ﹤0.01% | 1103 |
|
|
2021
Q1 | $471K | Buy |
22,850
+6,450
| +39% | +$133K | ﹤0.01% | 1407 |
|
|
2020
Q4 | $287K | Buy |
+16,400
| New | +$287K | ﹤0.01% | 1389 |
|